-
1Dissertation/ Thesis
-
2Dissertation/ Thesis
المؤلفون: 蔡伃婕
المساهمون: 田乃月, 郭柏麟, 嘉南藥理科技大學：生物科技系暨研究所
مصطلحات موضوعية: 人類非小細胞肺癌, Kotomolide A, 細胞凋亡, 細胞週期, 粒線體途徑, p53, ATM, Human non-small cell lung cancer cells, Apoptosis, Cell cycle, Mitochondrial pathway
وصف الملف: application/pdf; 1468117 bytes
Relation: 校內外完全公開 ，學年度：98，72頁; 參考文獻 1. Danesi R, Pasqualetti G, Giovannetti E, et al. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv Drug Deliv Rev. 2009;61(5):408-417. 2. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172(5):523-529. 3. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321(7257):323-329. 4. Iyengar P, Tsao MS. Clinical relevance of molecular markers in lung cancer. Surg Oncol. 2002;11(4):167-179. 5. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123(1 Suppl):21S-49S. 6. Visbal AL, Leighl NB, Feld R, Shepherd FA. Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. Chest. 2005;128(4):2933-2943. 7. Poirier MC. Chemical-induced DNA damage and human cancer risk. Nat Rev Cancer. 2004;4(8):630-637. 8. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001;15(17):2177-2196. 9. Wiencke JK. Impact of race/ethnicity on molecular pathways in human cancer. Nat Rev Cancer. 2004;4(1):79-84. 10. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342-348. 11.Murakami H, Nurse P. DNA replication and damage checkpoints and meiotic cell cycle controls in the fission and budding yeasts. Biochem J. 2000;349(Pt 1):1-12. 12. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153-166. 13. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer. 2008;98(3):523-528. 14. Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci. 2003;24(3):139-145. 15. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst. 2000;92(5):376-387. 16. Cam H, Dynlacht BD. Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell. 2003;3(4):311-316. 17. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer. 2003;3(12):931-943. 18. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20(15):1803-1815. 19. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805):770-776. 20. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256(1):42-49. 21. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene. 2003;22(20):3152-3161. 22. Timmer T, de Vries EG, de Jong S. Fas receptor-mediated apoptosis: a clinical application? J Pathol. 2002;196(2):125-134. 23. Schwarz M, Andrade-Navarro MA, Gross A. Mitochondrial carriers and pores: key regulators of the mitochondrial apoptotic program? Apoptosis. 2007;12(5):869-876. 24. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647-656. 25. Bruno T, De Nicola F, Iezzi S, et al. Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell. 2006;10(6):473-486. 26. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316(5828):1160-1166. 27. Srivastava N, Gochhait S, de Boer P, Bamezai RN. Role of H2AX in DNA damage response and human cancers. Mutat Res. 2009;681(2-3):180-188. 28. Lavin MF, Kozlov S. ATM activation and DNA damage response. Cell Cycle. 2007;6(8):931-942. 29. Dornan D, Shimizu H, Mah A, et al. ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Science. 2006;313(5790):1122-1126. 30. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 2004;64(7):2390-2396. 31. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 2004;4(10):793-805. 32. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8(4):275-283. 33. Lee YS, Wan J, Kim BJ, Bae MA, Song BJ. Ubiquitin-dependent degradation of p53 protein despite phosphorylation at its N terminus by acetaminophen. J Pharmacol Exp Ther. 2006;317(1):202-208. 34. Kulikov R, Winter M, Blattner C. Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J Biol Chem. 2006;281(39):28575-28583. 35. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24(17):2899-2908. 36. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003;22(56):9030-9040. 37. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2(8):594-604. 38. Chen CH, Lo WL, Liu YC, Chen CY. Chemical and cytotoxic constituents from the leaves of Cinnamomum kotoense. J Nat Prod. 2006;69(6):927-933. 39. Kuo PL, Chen CY, Tzeng TF, Lin CC, Hsu YL. Involvement of reactive oxygen species/c-Jun NH(2)-terminal kinase pathway in kotomolide A induces apoptosis in human breast cancer cells. Toxicol Appl Pharmacol. 2008;229(2):215-226. 40. Raez LE, Lilenbaum R. Chemotherapy for advanced non-small-cell lung cancer. Clin Adv Hematol Oncol. 2004;2(3):173-178. 41. Favaretto AG, Pasello G, Magro C. Second and third line treatment in advanced non-small cell lung cancer. Discov Med. 2009;8(43):204-209. 42. Maniadakis N, Fragoulakis V, Pallis AG, Simou E, Georgoulias V. Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis. Ann Oncol. 2009. 43. Suehisa H, Toyooka S. Adjuvant chemotherapy for completely resected non-small-cell lung cancer. Acta Med Okayama. 2009;63(5):223-230. 44. Bonomi PD. Implications of key trials in advanced nonsmall cell lung cancer. Cancer. 45. Kobayashi H, Uno T, Isobe K, et al. Radiation Pneumonitis Following Twice-daily Radiotherapy with Concurrent Carboplatin and Paclitaxel in Patients with Stage III Non-small-cell Lung Cancer. Jpn J Clin Oncol. 46. Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy. 2009;55(6):399-406. 47. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599. J Clin Oncol. 48. Hsu YL, Kuo PL, Lin CC. Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells. Life Sci. 2005;77(3):279-292. 49. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer. 2009;9(10):738-748. 50. Buschmann T, Adler V, Matusevich E, Fuchs SY, Ronai Z. p53 phosphorylation and association with murine double minute 2, c-Jun NH2-terminal kinase, p14ARF, and p300/CBP during the cell cycle and after exposure to ultraviolet irradiation. Cancer Res. 2000;60(4):896-900.; https://ir.cnu.edu.tw/handle/310902800/23116; https://ir.cnu.edu.tw/bitstream/310902800/23116/1/index.html